These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 36197410)

  • 1. TP53 or Not TP53: That Is the Question.
    Green SD; Zeidner JF
    Clin Cancer Res; 2022 Dec; 28(24):5235-5237. PubMed ID: 36197410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine.
    Pollyea DA; Pratz KW; Wei AH; Pullarkat V; Jonas BA; Recher C; Babu S; Schuh AC; Dail M; Sun Y; Potluri J; Chyla B; DiNardo CD
    Clin Cancer Res; 2022 Dec; 28(24):5272-5279. PubMed ID: 36007102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Venetoclax and azacitidine induced cytogenetic response in an elderly patient with IDH2- and DNMT3A-mutated refractory acute myeloid leukemia].
    Kunisada K; Matsuoka A; Yoshida S; Taoka T
    Rinsho Ketsueki; 2022; 63(12):1621-1625. PubMed ID: 36653133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy.
    Venugopal S; Shoukier M; Konopleva M; Dinardo CD; Ravandi F; Short NJ; Andreeff M; Borthakur G; Daver N; Pemmaraju N; Sasaki K; Montalban-Bravo G; Marx KR; Pierce S; Popat UR; Shpall EJ; Kanagal-Shamanna R; Garcia-Manero G; Kantarjian HM; Kadia TM
    Cancer; 2021 Oct; 127(19):3541-3551. PubMed ID: 34182597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shall We Dance: Evolving Partnerships of Targeted Therapies for AML.
    Perl AE; Vyas P
    Clin Cancer Res; 2022 Jul; 28(13):2719-2721. PubMed ID: 35452083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Azacitidine combined with venetoclax alleviates AML-MR with TP53 mutation in SDS: a case report and literature review.
    Ma C; Lang H; Chen Y; Yang L; Wang C; Han L; Chen X; Ma W
    Anticancer Drugs; 2024 Jul; 35(6):548-555. PubMed ID: 38502829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Short-term efficacy of venetoclax combined with azacitidine in acute myeloid leukemia: a single-institution experience].
    Yu WJ; Jia JS; Wang J; Tang FF; Gong LZ; Liu XH; Zhu XL; Zhao XS; Huang XJ; Jiang H
    Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):134-140. PubMed ID: 35381674
    [No Abstract]   [Full Text] [Related]  

  • 8. Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine.
    Venugopal S; Maiti A; DiNardo CD; Qiao W; Ning J; Loghavi S; Daver NG; Kadia TM; Rausch CR; Alvarado Y; Ohanian M; Sasaki K; Short NJ; Takahashi K; Yilmaz M; Ravandi F; Kantarjian HM; Konopleva MY
    Leuk Lymphoma; 2021 Dec; 62(14):3501-3505. PubMed ID: 34474640
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations.
    Pollyea DA; DiNardo CD; Arellano ML; Pigneux A; Fiedler W; Konopleva M; Rizzieri DA; Smith BD; Shinagawa A; Lemoli RM; Dail M; Duan Y; Chyla B; Potluri J; Miller CL; Kantarjian HM
    Clin Cancer Res; 2022 Jul; 28(13):2753-2761. PubMed ID: 35046058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia.
    Aldoss I; Zhang J; Pillai R; Shouse G; Sanchez JF; Mei M; Nakamura R; Stein AS; Forman SJ; Marcucci G; Pullarkat V
    Br J Haematol; 2019 Oct; 187(2):e45-e48. PubMed ID: 31441045
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine.
    Bories P; Prade N; Lagarde S; Cabarrou B; Largeaud L; Plenecassagnes J; Luquet I; De Mas V; Filleron T; Cassou M; Sarry A; Fornecker LM; Simand C; Bertoli S; Recher C; Delabesse E
    PLoS One; 2020; 15(10):e0238795. PubMed ID: 33001991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The propriety of upgrading responses to venetoclax + azacitidine in newly diagnosed patients with acute myeloid leukemia.
    Abbott D; Cherry E; Amaya M; McMahon C; Schwartz M; Winters A; Schowinsky J; Jordan CT; Smith C; Gutman JA; Pollyea DA
    Leuk Lymphoma; 2021 Jun; 62(6):1466-1473. PubMed ID: 33375853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic effects of PRIMA-1
    Maslah N; Salomao N; Drevon L; Verger E; Partouche N; Ly P; Aubin P; Naoui N; Schlageter MH; Bally C; Miekoutima E; Rahmé R; Lehmann-Che J; Ades L; Fenaux P; Cassinat B; Giraudier S
    Haematologica; 2020 Jun; 105(6):1539-1551. PubMed ID: 31488557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia.
    Patel KK; Zeidan AM; Shallis RM; Prebet T; Podoltsev N; Huntington SF
    Blood Adv; 2021 Feb; 5(4):994-1002. PubMed ID: 33591323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Palbociclib promotes the antitumor activity of Venetoclax plus Azacitidine against acute myeloid leukemia.
    Wang A; Fang M; Jiang H; Wang D; Zhang X; Tang B; Zhu X; Hu W; Liu X
    Biomed Pharmacother; 2022 Sep; 153():113527. PubMed ID: 36076608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).
    Badar T; Nanaa A; Atallah E; Shallis RM; Guilherme SCC; Goldberg AD; Saliba AN; Patel A; Bewersdorf JP; DuVall AS; Bradshaw D; Abaza Y; Murthy GSG; Palmisiano N; Zeidan AM; Kota V; Litzow MR
    Blood Cancer J; 2024 Feb; 14(1):32. PubMed ID: 38378617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Azacitidine and Venetoclax in AML.
    Moore JW; Pelcovits A; Reagan JL
    N Engl J Med; 2020 Nov; 383(21):2088. PubMed ID: 33207105
    [No Abstract]   [Full Text] [Related]  

  • 19. Azacitidine and Venetoclax in AML.
    Lucijanic M
    N Engl J Med; 2020 Nov; 383(21):2087-2088. PubMed ID: 33207104
    [No Abstract]   [Full Text] [Related]  

  • 20. Azacitidine and Venetoclax in AML.
    Chitikela S; Kumar L; Sahoo RK
    N Engl J Med; 2020 Nov; 383(21):2087. PubMed ID: 33207103
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.